Biomarkers of Durable Response With Intermittent Therapy With LGX818 and MEK162 Combined Therapy in Patients With BRAF Mutant Metastatic Melanoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2016
Price : $35 *
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Dec 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 08 Jun 2016 Status changed from not yet recruiting to recruiting.